<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Atropine (ophthalmic): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Atropine (ophthalmic): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Atropine (ophthalmic): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="103445" href="/d/html/103445.html" rel="external">see "Atropine (ophthalmic): Drug information"</a> and <a class="drug drug_patient" data-topicid="103447" href="/d/html/103447.html" rel="external">see "Atropine (ophthalmic): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F28406458"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Isopto Atropine [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871935"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Alcon Atropine;</li>
<li>Minims Atropine Sulfate</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F28680853"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Anticholinergic Agent, Ophthalmic</span>;</li>
<li>
<span class="list-set-name">Ophthalmic Agent, Mydriatic</span></li></ul></div>
<div class="block dop drugH1Div" id="F28406505"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d56fd235-f16a-4313-80e0-7eb3909b5d08">Amblyopia, healthy eye penalization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Amblyopia, healthy eye penalization:</b> Solution (1%):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥3 months and Children &lt;3 years: Ophthalmic: Instill 1 drop once daily to healthy eye</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥3 years and Adolescents: Ophthalmic: Solution (1%): Instill 1 drop once daily to healthy eye; dose may be repeated up to twice daily if needed</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bf7ca79a-532e-489d-819f-b576febc16b3">Mydriasis, cycloplegia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mydriasis, cycloplegia: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Solution (1%):</p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥3 months and Children &lt;3 years: Ophthalmic: Instill 1 drop 40 minutes prior to intended maximal dilation time; maximum dose: 1 drop per eye per day</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥3 years and Adolescents: Ophthalmic: Instill 1 drop 40 minutes prior to intended maximal dilation time; may repeat up to twice daily as needed</p>
<p style="text-indent:-2em;margin-left:4em;">Ointment: Infants, Children, and Adolescents: Ophthalmic: Apply a small amount in the conjunctival sac 1 to 2 times daily</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c434058b-79af-4d23-8df8-68f2cc410924">Inflammatory conditions of iris and uveal tract</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Infla</b>
<b>mmatory conditions of iris and uveal tract:</b> Infants, Children, and Adolescents: Ophthalmic: Ointment: Apply a small amount in the conjunctival sac 1 to 2 times daily</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51073331"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51073332"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F28406506"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="103445" href="/d/html/103445.html" rel="external">see "Atropine (ophthalmic): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d56fd235-f16a-4313-80e0-7eb3909b5d08">Amblyopia, healthy eye penalization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Amblyopia, healthy eye penalization:</b> Ophthalmic: Solution: Instill 1 drop in the conjunctiva of the sound eye (nonamblyopic eye) once daily on weekends or daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15522375']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15522375'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bf7ca79a-532e-489d-819f-b576febc16b3">Mydriasis, cycloplegia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mydriasis, cycloplegia:</b> Ophthalmic:</p>
<p style="text-indent:-2em;margin-left:4em;">Solution: Instill 1 drop in the conjunctiva 40 minutes prior to intended maximal dilation time; may repeat up to twice daily as needed.</p>
<p style="text-indent:-2em;margin-left:4em;">Ointment: Apply a small amount in the conjunctival sac 1 to 2 times daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="77a5d7c4-9e78-45f2-a62d-d6e879bc1400">Palliative care of respiratory secretions</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Palliative care of respiratory secretions (off-label use):</b> Sublingual (using 1% ophthalmic solution): Initial: 1 to 2 drops every 2 to 4 hours; usual dose range: 2 to 4 drops every 2 to 4 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22833553']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22833553'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990318"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Use caution; dosage adjustment may be required.</p></div>
<div class="block doha drugH1Div" id="F50987649"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F28406477"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Severity and frequency of adverse reactions are dose related.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing, hypotension, increased blood pressure, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Contact dermatitis, xeroderma</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Delirium, irritability, restlessness</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, decreased lacrimation, decreased visual acuity (reversible, healthy eye) (Scheiman 2008), eye irritation, eye pain, eyelid edema, papillary conjunctivitis, photophobia, stinging of eyes, superficial keratitis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dry throat, respiratory depression</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F28406474"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Hypersensitivity to atropine or any component of the formulation; primary glaucoma or tendency toward angle-closure glaucoma (narrowing or closure of the anterior chamber angle).</p></div>
<div class="block war drugH1Div" id="F28406475"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Elevated BP: May occur due to systemic absorption following conjunctival instillation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Photophobia/blurred vision: May last up to 2 weeks due to pupil unresponsiveness and cycloplegia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Brain damage: Use with caution in patients with brain damage; these patients are particularly susceptible to CNS disturbances and cardiopulmonary and GI toxicity from systemic absorption of atropine.</p>
<p style="text-indent:-2em;margin-left:4em;">• Down syndrome: Use with caution in patients with Down syndrome; these patients are particularly susceptible to CNS disturbances and cardiopulmonary and GI toxicity from systemic absorption of atropine.</p>
<p style="text-indent:-2em;margin-left:4em;">• Spastic paralysis: Use with caution in patients with spastic paralysis; these patients are particularly susceptible to CNS disturbances and cardiopulmonary and GI toxicity from systemic absorption of atropine.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzalkonium chloride: Some products may contain benzalkonium chloride which may be absorbed by soft contact lenses; avoid contact use during treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: To avoid precipitating angle closure glaucoma, an estimation of the depth of the anterior chamber angle should be made prior to use.</p></div>
<div class="block foc drugH1Div" id="F28406524"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Ointment, Ophthalmic, as sulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1% (3.5 g [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Ointment, Ophthalmic, as sulfate [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1% (3.5 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Ophthalmic, as sulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Isopto Atropine: 1% (5 mL [DSC]) [contains benzalkonium chloride]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1% (2 mL, 5 mL, 15 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Ophthalmic, as sulfate [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1% (10 ea)</p></div>
<div class="block geq drugH1Div" id="F28406462"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F28406527"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Ointment</b> (Atropine Sulfate Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1% (per gram): $10.67</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Atropine Sulfate Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1% (per mL): $21.00 - $23.93</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871936"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Ophthalmic: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1% (0.3 mL, 0.5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Ophthalmic, as sulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Alcon Atropine: 1% (5 mL) [contains benzalkonium chloride]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1% (5 mL)</p></div>
<div class="block admp drugH1Div" id="F52614593"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Ophthalmic: Wash hands prior to use.</p>
<p style="text-indent:-2em;margin-left:2em;">Solution: Instill solution into conjunctival sac of affected eye(s); Avoid contact of bottle tip with eye or skin; apply gentle pressure to lacrimal sac during and immediately following instillation (1 minute) or instruct patient to gently close eyelid after administration, to decrease systemic absorption of ophthalmic drops (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8100087','lexi-content-ref-6704011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8100087','lexi-content-ref-6704011'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:2em;">Ointment: Place a small amount of ointment into the conjunctival sac of the affected eye(s)</p></div>
<div class="block adm drugH1Div" id="F28406511"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Ophthalmic:</b> For topical ophthalmic use only. Wash hands before and after use. Avoid touching tip of applicator to eye or other surfaces. Finger pressure should be applied to lacrimal sac for 1 to 3 minutes after instillation to decrease risk of absorption and systemic reactions.</p></div>
<div class="block sts drugH1Div" id="F28406489"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Solution: Store at 2°C to 25°C (36°F to 77°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Ointment: Store at 15°C to 25°C (59°F to 77°F).</p></div>
<div class="block usep drugH1Div" id="F53571243"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Ophthalmic solution: Produce mydriasis and cycloplegia; produce papillary dilation for cycloplegic refraction, penalization of healthy eye in the treatment of amblyopia (All indications: FDA approved in ages ≥3 months and adults)</p>
<p style="text-indent:-2em;margin-left:2em;">Ophthalmic ointment: Produce mydriasis and cycloplegia; produce papillary dilation for cycloplegic refraction, papillary dilation in inflammatory conditions of iris or uveal tract (FDA approved in pediatric patients [age not specified] and adults)</p></div>
<div class="block mst drugH1Div" id="F28406450"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">International issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Atropt [Australia and New Zealand] may be confused with Azopt brand name for brinzolamide [US, Canada, and multiple international markets]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F28406484"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F28406481"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Anticholinergic Agents may enhance the anticholinergic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Atropine (Ophthalmic).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: Anticholinergic Agents may enhance the adverse/toxic effect of Opioid Agonists. Specifically, the risk for constipation and urinary retention may be increased with this combination. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.  Management:  Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: Anticholinergic Agents may diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents.  Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F28406471"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Atropine crosses the placenta following systemic maternal use (Shutt 1979). Atropine is systemically available following ophthalmic administration. If ophthalmic agents are needed during pregnancy, the minimum effective dose should be used in combination with punctal occlusion to decrease potential exposure to the fetus (Samples 1988).</p></div>
<div class="block mopp drugH1Div" id="F53571242"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Heart rate, blood pressure</p></div>
<div class="block pha drugH1Div" id="F28406493"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Blocks the action of acetylcholine that induces mydriasis and allows the radial pupillary dilator muscle to contract resulting in dilation of the pupil; induces cycloplegia by paralysis of the ciliary muscle. In amblyopia, use temporarily blurs sight in the healthy eye and encourages the use of the amblyopic eye.</p></div>
<div class="block phk drugH1Div" id="F28406495"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Ophthalmic solution: Within minutes; maximum effect: within hours (3 hours [Matta 2013]).</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Multiple days; visual acuity near normal at 4 days postadministration (Matta 2013).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Well absorbed from all dosage forms.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via enzymatic hydrolysis.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Ophthalmic solution: 64% ± 29% (range: 19% to 95%).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 2.5 ± 0.8 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 28 ± 27 minutes (range: 3 to 60 minutes).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (13% to 50% as unchanged drug and metabolites).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F30134581"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Apitropin | Atropine Chibret | Isopto atropine</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Atropina poen | Isopto atropina</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Atropine sulphate | Atropt | Eikance</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Atrogen | Atropin | Atropine | Itropine | Mydripine</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Alcon atropine | Atropine bournonville pharm | Atropine viatris</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Atropin sulfate | Atropin vision | Isopto atropine</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Atropina</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Atropine dispersa | Atropine sdu faure | Bellafit N | Skiatropin</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Atropine alcon</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Atropine</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Atropina | Isopto atropina</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Atropin | Atropin edo | Atropin-augenoel | Atropinol | Hevertospast | Noxenur s</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Atropina | Isopto atropina</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Atropina | Isopto atropina</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Atropin | Atropin pos | Atropine | Atropine sulphate | Isopto atropine | Myatro | Oftan-atropin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Atropine | Atropine sulphate | Atropisol | Isopto atropine</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Atropina llorens | Colircusi atropina | Colirio oculos atropina | Oftalmolosa cusi atropina</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Atropocil</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Isopto atropin | Oftan-atropin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Atropine alcon | Atropine faure | Chibro atropine | Genatropine</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Atropine | Atropine sulph | Atropine sulphate | Isopto atropine | Mf atropine</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Atropine | Atropine sulfate cooper | Atropine sulphate | Atrosol | Myopine</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Cendo Tropine | Isotic cycloma</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Isopto atropine</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Atropine | Atrospan</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Ataron | Atpine | Atro | Atrokid | Atromet | Atrone | Atroped | Atropine | Atropine sulphate | Atroren-p | Atrosulph | Atrosun | Atrozen | Bellpino atrin | Bysipin | Kaitro | Kidtro | Loatro | Myatro | Myotry | Opta | Ped eye | Pedatro | Topin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Atropina | Atropina lux | Liotropina</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Apitropin | Atropine</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Atropine nitten | Atropine sulfate nitto | Atropine Sulfate Senju | Ryuato</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Atrop | Isopto atropine</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Atropine | Isopto atropine | Ocutropin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Atropine</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Apo atropine | Atropine | Isopto atropine | Spersatropine</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Atropin | Atropin pos | Atropin sulfate | Isopto atropin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Atropin | Atropine alcon</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Atropin sulfate | Atropine sulphate | Isopto atropine</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Atro grin | Atro ofteno | Atro Ofteno AL | Atropina | Atropina grin</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Atropine | Isopto atropine | Myopine</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Linkabs atropine</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Atropinesulf | Atropinesulfaat pch | Atropinesulfaat ratiopharm</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Atropin</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Atropine sulphate | Atropt</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Atropina | Atropina sulfato | Isopto atropina</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Atropine novartis | Atroptal | Isopto atropine</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Atropine | Atropisol | Ethiatropine | Isopto atropine | Opta atropine | Orbatropin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Atropin pos | Atropinum sulfuricum</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Atropisol | Isopto atropine</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Atropocil | Colircusi atropina</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Isopto atropina</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Riatropine</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Apitropin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Atromed | Atropin | Atropine</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apitropin | Atropine | Atropine sulphate | Isopto atropine | Riatropine</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Atropin chauvin | Isopto atropin</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Atropine | Atropine sulphate | Atrosol | Isopto atropine | Minims atropine sulfate</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Atropin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Atropin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Atropine | Isopto atropine</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Apitropin | Atropine | Atropine martinet</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Atrosol | Midrisol</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Antol | Apine | Atropine | Atropine "patron" | Atropine sulphate | Colircusi atropine | Tropine</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Atropin sulfate</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Atropine</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Atropina | Isopto atropina</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Atropicel | Atropina | Isopto atropina</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Atropine | Atropine sulphate | Isopto atropine</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Atropen p</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Isopto atropine</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Bausch.1">
<a name="Bausch.1"></a>Atropine ointment [prescribing information]. Tampa, FL Bausch &amp; Lomb; June 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Akorn.1">
<a name="Akorn.1"></a>Atropine solution [prescribing information]. Lake Forest, IL: Akorn; July 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22795904">
<a name="22795904"></a>Heisler M, Hamilton G, Abbott A, Chengalaram A, Koceja T, Gerkin R. Randomized double-blind trial of sublingual atropine vs. placebo for the management of death rattle. <i>J Pain Symptom Manage</i>. 2013;45(1):14-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-ophthalmic-pediatric-drug-information/abstract-text/22795904/pubmed" id="22795904" target="_blank">22795904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Alcon.1">
<a name="Alcon.1"></a>Isopto (atropine) [prescribing information]. Fort Worth, TX: Alcon; December 2016.</div>
</li>
<li>
<div class="reference">
                  Matta N, Silbert DI. Effects of atropine on the accommodative system: parameters to consider in its use for penalization treatment of amblyopia. <i>Binocul Vis Strabolog Q Simms Romano</i>. 2013;28(1):39-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-ophthalmic-pediatric-drug-information/abstract-text/23521035/pubmed" id="23521035" target="_blank">23521035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nelson.1996">
<a name="Nelson.1996"></a>Nelson WE, Behrman RE, Kliegman RM, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 15th ed. Philadelphia, PA: WB Saunders Company; 1996.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22833553">
<a name="22833553"></a>Protus BM, Grauer PA, Kimbrel JM. Evaluation of atropine 1% ophthalmic solution administered sublingually for the management of terminal respiratory secretions. <i>Am J Hosp Palliat Care</i>. 2013;30(4):388-392. doi: 10.1177/1049909112453641.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-ophthalmic-pediatric-drug-information/abstract-text/22833553/pubmed" id="22833553" target="_blank">22833553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15522375">
<a name="15522375"></a>Repka MX, Cotter SA, Beck RW, et al; Pediatric Eye Disease Investigator Group. A randomized trial of atropine regimens for treatment of moderate amblyopia in children. <i>Ophthalmology</i>. 2004;111(11):2076-85. doi:10.1016/j.ophtha.2004.04.032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-ophthalmic-pediatric-drug-information/abstract-text/15522375/pubmed" id="15522375" target="_blank">15522375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24789375">
<a name="24789375"></a>Repka MX, Kraker RT, Holmes JM, et al; Pediatric Eye Disease Investigator Group. Atropine vs patching for treatment of moderate amblyopia: follow-up at 15 years of age of a randomized clinical trial. <i>JAMA Ophthalmol</i>. 2014;132(7):799-805.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-ophthalmic-pediatric-drug-information/abstract-text/24789375/pubmed" id="24789375" target="_blank">24789375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2903673">
<a name="2903673"></a>Samples JR, Meyer SM. Use of ophthalmic medications in pregnant and nursing women. <i>Am J Ophthalmol</i>. 1988;106(5):616-623.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-ophthalmic-pediatric-drug-information/abstract-text/2903673/pubmed" id="2903673" target="_blank">2903673</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19064841">
<a name="19064841"></a>Scheiman MM, Hertle RW, Kraker RT, et al; Pediatric Eye Disease Investigator Group. Patching vs atropine to treat amblyopia in children aged 7 to 12 years: a randomized trial. <i>Arch Ophthalmol</i>. 2008;126(12):1634-1642.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-ophthalmic-pediatric-drug-information/abstract-text/19064841/pubmed" id="19064841" target="_blank">19064841</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22747099">
<a name="22747099"></a>Shinjo T, Okada M. Atropine eyedrops for death rattle in a terminal cancer patient. <i>J Palliat Med</i>. 2013;16(2):212-213.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-ophthalmic-pediatric-drug-information/abstract-text/22747099/pubmed" id="22747099" target="_blank">22747099</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-382907">
<a name="382907"></a>Shutt LE, Bowes JB. Atropine and hyoscine. <i>Anaesthesia</i>. 1979;34(5):476-490. Review.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-ophthalmic-pediatric-drug-information/abstract-text/382907/pubmed" id="382907" target="_blank">382907</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8100087">
<a name="8100087"></a>Urtti A, Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs. <i>Surv Ophthalmol</i>. 1993;37(6):435-456.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-ophthalmic-pediatric-drug-information/abstract-text/8100087/pubmed" id="8100087" target="_blank">8100087</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6704011">
<a name="6704011"></a>Zimmerman TJ, Kooner KS, Kandarakis AS, Ziegler LP. Improving the therapeutic index of topically applied ocular drugs.<i> Arch Ophthalmol</i>. 1984;102(4):551-553.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-ophthalmic-pediatric-drug-information/abstract-text/6704011/pubmed" id="6704011" target="_blank">6704011</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 103679 Version 226.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
